Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diphenhydramine (Benadryl) Clear all
Active, not recruiting Phase 1 Interventional Results available

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Diphenhydramine in Children and Adolescents

NCT00762749
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
diphenhydramine HCl
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"

NCT03081416
View directory record Official record
Conditions
Headache, Intranasal Ketamine
Interventions
Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 14, 2026, 12:17 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Results available

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

NCT03657810
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 5 mg, Norco, Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Results available

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

NCT02023164
View directory record Official record
Conditions
Acute Urticaria
Interventions
JDP-205 Injection, Diphenhydramine
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

Histamine Glutamate Antagonism in Stroke

NCT02142712
View directory record Official record
Conditions
Acute Cerebrovascular Accident, Cerebral Edema
Interventions
Diphenhydramine, Pantoprazole, Famotidine, Dextromethorphan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating the Endothelium to Restore Insulin Sensitivity

NCT00402194
View directory record Official record
Conditions
Obesity, Insulin Resistance, Impaired Glucose Tolerance, Pre-diabetes
Interventions
Losartan
Drug
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 14, 2026, 12:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy

NCT02300727
View directory record Official record
Conditions
Mucositis
Interventions
Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin
Drug
Lead sponsor
Amy Beres
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Muscle Strength Maintenance in Older Adults

NCT01989793
View directory record Official record
Conditions
Sarcopenia
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 14, 2026, 12:17 AM EDT
Terminated Phase 1 Interventional Results available

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

NCT02188719
View directory record Official record
Conditions
Liver Transplantation
Interventions
Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Results available

Metoclopramide for Migraine: A Dose Finding Study

NCT00682734
View directory record Official record
Conditions
Migraine
Interventions
metoclopramide, Diphenhydramine 25mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 14, 2026, 12:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Losartan, Placebo - Losartan
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 1 Interventional

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT04106856
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255
View directory record Official record
Conditions
Healthy
Interventions
lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 14, 2026, 12:17 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762716
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Requiring Hospitalization

NCT04312009
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 14, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

NCT04518293
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
Drug
Lead sponsor
George Medicines PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
1,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 14, 2026, 12:17 AM EDT